Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07256665 · ClinicalTrials.gov registry record · NA
The Cracking Consciousness Study With Monroe & Neuphoria
A NA study, sponsored by Efforia.
- Completed
- Registry status
- NA
- Development phase
- 271
- Enrollment target
NCT07256665: Completed NA study, sponsored by Efforia.
NCT07256665 is a NA study that has completed, run by Efforia. The registered enrollment target is 271 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07256665, a NA study, has completed, sponsored by Efforia.
- COMPLETED
- Registry status
- NA
- Development phase
- 271 participants
- Enrollment target
Study Summary
You've explored the Monroe Focus levels. But, Bob Monroe said, "You might believe something, but you won't understand it until you can measure it with objective data." Now, for the first time, we can measure them. In partnership with Neuphoria, we're launching a groundbreaking EEG study to define Higher States of Consciousness. Join the World's First higher states of Consciousness Study.
Primary Outcome
Neuphoria's wearable neurofeedback system harnesses real-time EEG to generate a rich, multidimensional cognitive profile by measuring five core metrics-mental state, mindset, nervous system activity, emotion, and breathing patterns-all displayed via its biohacking dashboard to offer users nuanced insights into their cognitive and physiological functioning
Interventions
- DEVICE Neuphoria Wearable
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2025-08-10 |
| Est. Completion | 2026-01-10 |
| Phase | NA |
What the finished NCT07256665 record still lists
NCT07256665 is an interventional study that assigns participants to a tested intervention. The registered 271 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which Neuphoria Wearable is the first listed.
NCT07256665 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07256665 about?
NCT07256665 is a clinical study titled "The Cracking Consciousness Study With Monroe & Neuphoria". You've explored the Monroe Focus levels. But, Bob Monroe said, "You might believe something, but you won't understand it until you can measure it with objective data." Now, for the first time, we can measure them. In partnership with Neuphoria, we're launching a groundbreaking EEG study to define Hi...
What is the current status of trial NCT07256665?
This trial is currently completed. It is a NA study. The enrollment target is 271 participants. The study started on 2025-08-10. Estimated completion is 2026-01-10.
What interventions are being tested in trial NCT07256665?
The interventions under investigation include: Neuphoria Wearable (DEVICE).
Who is sponsoring clinical trial NCT07256665?
This trial is sponsored by Efforia, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07256665's enrollment target sits among peer trials
271 387th of 2000 higher than 1,614 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03609216 · 271 participants · Phase 2
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI